These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 19088689)

  • 1. The evolution in the use of MIBG in more than 25 years of experimental and clinical applications.
    Rufini V; Shulkin B
    Q J Nucl Med Mol Imaging; 2008 Dec; 52(4):341-50. PubMed ID: 19088689
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radioiodinated metaiodobenzylguanidine (MIBG): radiochemistry, biology, and pharmacology.
    Vallabhajosula S; Nikolopoulou A
    Semin Nucl Med; 2011 Sep; 41(5):324-33. PubMed ID: 21803182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential increased tumor-dose delivery with combined 131I-MIBG and 90Y-DOTATOC treatment in neuroendocrine tumors: a theoretic model.
    Madsen MT; Bushnell DL; Juweid ME; Menda Y; O'Dorisio MS; O'Dorisio T; Besse IM
    J Nucl Med; 2006 Apr; 47(4):660-7. PubMed ID: 16595501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radioiodinated metaiodobenzylguanidine in the diagnosis and therapy of carcinoid tumors.
    Khan MU; Morse M; Coleman RE
    Q J Nucl Med Mol Imaging; 2008 Dec; 52(4):441-54. PubMed ID: 19088697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The evolution in the use of MIBG scintigraphy in pheochromocytomas and paragangliomas.
    Rufini V; Treglia G; Perotti G; Giordano A
    Hormones (Athens); 2013; 12(1):58-68. PubMed ID: 23624132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimizing MIBG therapy of neuroendocrine tumors: preclinical evidence of dose maximization and synergy.
    Mairs RJ; Boyd M
    Nucl Med Biol; 2008 Aug; 35 Suppl 1():S9-20. PubMed ID: 18707637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imaging hNET reporter gene expression with 124I-MIBG.
    Moroz MA; Serganova I; Zanzonico P; Ageyeva L; Beresten T; Dyomina E; Burnazi E; Finn RD; Doubrovin M; Blasberg RG
    J Nucl Med; 2007 May; 48(5):827-36. PubMed ID: 17475971
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficient production of therapeutic doses of [131I]-metaiodobenzylguanidine for clinical use.
    Prabhakar G; Mathur A; Shunmugam G; Teje YD; Sachdev SS; Sivaprasad N
    Appl Radiat Isot; 2011 Jan; 69(1):63-7. PubMed ID: 20933432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiolabeled metaiodobenzylguanidine for imaging and therapy of neuroblastoma.
    Taggart D; Dubois S; Matthay KK
    Q J Nucl Med Mol Imaging; 2008 Dec; 52(4):403-18. PubMed ID: 19088694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Meta-iodobenzylguanidine derivatives containing a second guanidine moiety.
    Vaidyanathan G; Shankar S; Affleck DJ; Alston K; Norman J; Welsh P; LeGrand H; Zalutsky MR
    Bioorg Med Chem; 2004 Apr; 12(7):1649-56. PubMed ID: 15028258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Meta-iodobenzylguanidine and analogues: chemistry and biology.
    Vaidyanathan G
    Q J Nucl Med Mol Imaging; 2008 Dec; 52(4):351-68. PubMed ID: 19088690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radioiodinated metaiodobenzylguanidine treatment of neuroendocrine tumors in adults.
    Postema EJ; McEwan AJ
    Cancer Biother Radiopharm; 2009 Oct; 24(5):519-25. PubMed ID: 19877881
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical assessment of strategies for enhancement of metaiodobenzylguanidine therapy of neuroendocrine tumors.
    Mairs RJ; Boyd M
    Semin Nucl Med; 2011 Sep; 41(5):334-44. PubMed ID: 21803183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intraarterial 131I-MIBG therapy of neuroendocrine tumors with liver metastases.
    Popp M; Strumpf A; Zöphel K; Stroszczynski C; Kotzerke J
    Nuklearmedizin; 2010; 49(1):N2-3. PubMed ID: 20336828
    [No Abstract]   [Full Text] [Related]  

  • 15. MIBG for diagnosis and therapy of medullary thyroid carcinoma: is there still a role?
    Castellani MR; Seregni E; Maccauro M; Chiesa C; Aliberti G; Orunesu E; Bombardieri E
    Q J Nucl Med Mol Imaging; 2008 Dec; 52(4):430-40. PubMed ID: 19088696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Localization of metastases from malignant pheochromocytoma in patients undergoing 131I-MIBG therapy with manually fused 123I-MIBG SPECT and CT images.
    Kizu H; Takayama T; Tsushima H; Noguchi A; Nakajima K; Onoguchi M; Kinuya S
    J Nucl Med Technol; 2008 Dec; 36(4):186-8. PubMed ID: 19008288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 131I-MIBG Therapy in a Metastatic Small Bowel Neuroendocrine Tumor Patient Undergoing Hemodialysis.
    Rahimi B; Makis W; Riauka TA; McEwan AJ; Morrish D
    Clin Nucl Med; 2017 May; 42(5):350-353. PubMed ID: 28240668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Draft guidelines regarding appropriate use of (131)I-MIBG radiotherapy for neuroendocrine tumors : Guideline Drafting Committee for Radiotherapy with (131)I-MIBG, Committee for Nuclear Oncology and Immunology, The Japanese Society of Nuclear Medicine.
    Kinuya S; Yoshinaga K; Higuchi T; Jinguji M; Kurihara H; Kawamoto H;
    Ann Nucl Med; 2015 Jul; 29(6):543-52. PubMed ID: 25773397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive value of cardiac autonomic indexes and MIBG washout in ICD recipients with mild to moderate heart failure.
    Koutelou M; Katsikis A; Flevari P; Theodorakis G; Livanis E; Georgiadis M; Voudris V; Kremastinos D
    Ann Nucl Med; 2009 Sep; 23(7):677-84. PubMed ID: 19662346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In-house preparation of iodine -131 metaiodo benzyl guanidine for scintigraphy of neuroendocrine tumors. Fourteen years experience in South India.
    Oommen R; Shanthly N; Subramani N; Devadhas D; Hephzibah J; Theodore B; Srinivasan J
    Hell J Nucl Med; 2007; 10(3):164-6. PubMed ID: 18084657
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.